Title: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
Authors: van Krieken, J. H. J. M ×
Jung, A
Kirchner, T
Carneiro, F
Seruca, R
Bosman, F. T
Quirke, P
Flejou, J. F
Hansen, T. Plato
De Hertogh, Gert
Jares, P
Langner, C
Hoefler, G
Ligtenberg, M
Tiniakos, D
Tejpar, Sabine
Bevilacqua, G
Ensari, A #
Issue Date: Nov-2008
Publisher: Springer-Verlag
Series Title: Virchows Archiv vol:453 issue:5 pages:417-431
Abstract: Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
ISSN: 0945-6317
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Cell & Tissue Research
Translational Research in GastroIntestinal Disorders
Molecular Digestive Oncology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science